Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMihaly Hajos, PharmD, PhD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Mihaly Hajos is a Professor Adjunct at the Section of Comparative Medicine, leading the Laboratory of Translational Neuropharmacology. He received a Pharm.D. degree from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and a Ph.D. from University of Goteborg, Sweden. His research interest includes neurobiology and pharmacology of psychiatric and neurological disorders, application of systems electrophysiology in drug discovery, and translational aspects of neurophysiological measures from preclinical to clinical studies.
Last Updated on April 07, 2025.
Appointments
Comparative Medicine
Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of Goteborg, Pharmacology, Medical School
- PharmD
- A. Szent-Gyorgyi Medical University, Physiology and Pathophysiology
Research
Copy Link
Overview
Medical Research Interests
Mental Disorders
ORCID
0000-0002-5379-8576
Research at a Glance
Yale Co-Authors
Frequent collaborators of Mihaly Hajos's published research.
Publications Timeline
A big-picture view of Mihaly Hajos's research output by year.
Tamas Horvath, DVM, PhD
Milan Stoiljkovic, MD, PhD
Deepak Cyril Dsouza, MBBS, MD
113Publications
5,276Citations
Publications
2025
Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Morgan M, Christensen J, Sabbagh M, Lee L, Hajós M, Riddle J, Seshagiri C, Howell C, Mallinckrodt C, Hendrix S. Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70118. PMID: 40501511, PMCID: PMC12152371, DOI: 10.1002/trc2.70118.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWhole-brain volumeMini-Mental State ExaminationOpen-label extensionMild to moderate ADEvoked gamma oscillationsGamma oscillationsADCS-ADLActivities of daily livingWhole-brain atrophyPost Hoc AnalysisMeasures of whole-brain volumeMini-MentalState ExaminationAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseaseMonths of active treatmentDaily livingActive treatmentRandomized controlled trial phaseOpen-label extension phaseModerate Alzheimer's diseaseWhole-brain volume changesEffect of active treatmentMonths of progressionMemory consolidationA novel method for harmonization of PET image spatial resolution without phantoms
Carbonell F, Zijdenbos A, Hempel E, Hajós M, Bedell B. A novel method for harmonization of PET image spatial resolution without phantoms. EJNMMI Physics 2025, 12: 23. PMID: 40082316, PMCID: PMC11906943, DOI: 10.1186/s40658-025-00740-9.Peer-Reviewed Original ResearchCitationsConceptsPhantom imagesGroup of imagesLinear regression problemSpatial resolutionAlzheimer's Disease Neuroimaging InitiativeRegression problemPET imagingHoffman phantomResolution estimatesEstimation of spatial resolutionMultiple linear regression problemFourier domainImage spatial resolutionPhysical phantomAcquisition of imagesMaximum difference valuePhantom dataPhantomReconstruction parametersScanner modelsIn-planeVoxel sizeFourier transformSubject's PET imageIntensity plotsAlpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
Babiloni C, Arakaki X, Baez S, Barry R, Benussi A, Blinowska K, Bonanni L, Borroni B, Bayard J, Bruno G, Cacciotti A, Carducci F, Carino J, Carpi M, Conte A, Cruzat J, D'Antonio F, Della Penna S, Del Percio C, De Sanctis P, Escudero J, Fabbrini G, Farina F, Fraga F, Fuhr P, Gschwandtner U, Güntekin B, Guo Y, Hajos M, Hallett M, Hampel H, Hanoğlu L, Haraldsen I, Hassan M, Hatlestad-Hall C, Horváth A, Ibanez A, Infarinato F, Jaramillo-Jimenez A, Jeong J, Jiang Y, Kamiński M, Koch G, Kumar S, Leodori G, Li G, Lizio R, Lopez S, Ferri R, Maestú F, Marra C, Marzetti L, McGeown W, Miraglia F, Moguilner S, Moretti D, Mushtaq F, Noce G, Nucci L, Ochoa J, Onorati P, Padovani A, Pappalettera C, Parra M, Pardini M, Pascual-Marqui R, Paulus W, Pizzella V, Prado P, Rauchs G, Ritter P, Salvatore M, Santamaria-García H, Schirner M, Soricelli A, Taylor J, Tankisi H, Tecchio F, Teipel S, Kodamullil A, Triggiani A, Valdes-Sosa M, Valdes-Sosa P, Vecchio F, Vossel K, Yao D, Yener G, Ziemann U, Kamondi A. Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true? Clinical Neurophysiology 2025, 172: 33-50. PMID: 39978053, DOI: 10.1016/j.clinph.2025.02.256.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPathological agingAlzheimer's diseaseExpert panelAlpha rhythmAD patient’s qualityQuality of lifeAging-Alzheimer's AssociationCognitive impairmentCognitive declineClinical workupNeuroscience SocietyCortical circuitsAD patientsUS National InstitutesOlder adultsRoutine useSenile dementiaDecades of researchPatients' qualityClinical guidelinesOscillatory synchronizationCause of dementiaClinical applicationNIA-AADementiaCSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment
Hajós M, Pandey K, Singer A, Duong D, Bitarafan S, Shpokayte M, Malchano Z, Kern R, Lah J, Levey A, Seyfried N. CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70051. PMID: 39935616, PMCID: PMC11812123, DOI: 10.1002/trc2.70051.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCellular lipid transportLipid transportWeeks of treatmentProteomic changesAlzheimer's diseaseCerebrospinal fluidGamma oscillationsTandem mass tag-mass spectrometryNeuroimmune functionDifferential expression analysisMyelin preservationUnbiased proteomic analysisBiological pathway analysisTreatment of ADSynaptic biologyAffected proteinsProteome modulationPhosphatidylcholine biosynthesisReduced brain volumeCSF proteome changesProtein networkSensory‐evoked gamma oscillationsExpression analysisBiochemical pathwaysBiological pathways
2024
OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Kuang Z, Houser C, Hajos M, Vaughan B, Hendrix S. OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition. Alzheimer's & Dementia 2024, 20: e094669. PMCID: PMC11712459, DOI: 10.1002/alz.094669.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsADCS-ADLSham treatmentMeasures of functionIndividual patient changesComposite measureMild-moderate Alzheimer's diseaseAt-homeMild-moderate ADTreatment effectsBaseline measurementsAlzheimer's diseaseEstimated time savingsPatients changesOne-hourMMSEPost-hocActive treatmentOutcomesTrialsBaselineAdverse eventsADLOVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Kern R, Kuang C, Seshagiri C, Konisky A, Galley A, Boasso A, Hempel E, Malchano Z, Vaughan B, Cimenser A, Da X, Shpokayte M, Hajos M. OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis. Alzheimer's & Dementia 2024, 20: e085091. PMCID: PMC11714597, DOI: 10.1002/alz.085091.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsAPOE4 carrier statusBaseline subgroupsMild-moderate Alzheimer's diseasePhase 2 clinical trialIndicators of neurodegenerationBrain atrophyBrain volume outcomesBaseline ageBrain volume lossWhole brain volume lossCarrier statusWBVMagnetic resonance imagingAlzheimer's diseaseBaseline covariatesMonth 6Subgroup analysisAt-homeParticipantsClinical trialsTreatment outcomesActive treatmentOne-hourSham treatmentOVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease
Da X, Hempel E, Hajos M, Kern R, Cimenser A. OVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease. Alzheimer's & Dementia 2024, 20: e085446. PMCID: PMC11714734, DOI: 10.1002/alz.085446.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMonth 3Midsagittal planeDiffusion tensor imagingPhase 3 clinical trialsRegional structural alterationsCorpus callosumT1w MRI imagesMonths of treatmentCommissural white matter tractsCorpus callosum atrophyWhite matter atrophyAlzheimer's diseaseSensory stimulationMonth 6CC atrophyClinical trialsSham groupWhite matter tractsGamma frequenciesVisual stimulationResonance imagingMechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins
Shpokayte M, Pandey K, Singer A, Doung D, Lah J, Levey A, Seyfried N, Malchano Z, Kern R, Hajos M. Mechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins. Alzheimer's & Dementia 2024, 20: e087390. PMCID: PMC11715388, DOI: 10.1002/alz.087390.Peer-Reviewed Original ResearchConceptsCell surface receptorsAlzheimer's diseaseSurface receptorsCo-expression modulesDifferential expression analysisAD-related pathologyContext of ADProteome databasePost-synaptic densityProteomic analysisExpression analysisSynaptic proteinsCerebrospinal fluid proteomeCerebrospinal fluidProteinSignificance thresholdMyelin-related proteinsSynaptic regulationMechanism of actionSensory stimulationCellsPrecursor cellsRegulationCerebrospinal fluid samplesCerebrospinal fluid proteinSpectris™ treatment preserves corpus callosum structure in Alzheimer's disease
Da X, Hempel E, Brickman A, Hajós M, Kern R, Cimenser A. Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease. Frontiers In Neurology 2024, 15: 1452930. PMID: 39479005, PMCID: PMC11522122, DOI: 10.3389/fneur.2024.1452930.Peer-Reviewed Original ResearchCitationsAltmetricParallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia
Jiang Y, Neal J, Sompol P, Yener G, Arakaki X, Norris C, Farina F, Ibanez A, Lopez S, Al‐Ezzi A, Kavcic V, Güntekin B, Babiloni C, Hajós M. Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia. Alzheimer's & Dementia 2024, 20: 7296-7319. PMID: 39206795, PMCID: PMC11485397, DOI: 10.1002/alz.14089.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCOVID-19 patientsEEG abnormalitiesNeurophysiological abnormalitiesMild cognitive impairmentCognitive deficitsBrain activityAstrocyte reactivityPredicting long-term outcomesCognitive impairmentLong-term outcomesSlowing of EEGCognitive declineEfficacy of therapeutic interventionsIntrinsic brain activityLong COVIDElectrophysiological brain activityEEG slowingNeurological complicationsEpileptiform activityEEG monitoringEarly stages of neurodegenerative diseasesCognitive decline riskNeurovascular injuryLong COVID-19Acute phase
Get In Touch
Copy Link